New clinical trial focused on pulmonary complications in COVID-19 patients

Michael Walter | | Cardiovascular Business | COVID-19

The Montreal Heart Institute has launched a new clinical trial aimed at improving care for patients who have been diagnosed with COVID-19.

The COLCORONA trial is the work of the Montreal Health Innovations Coordinating Center, with support coming from Pharmascience, CGI and Quebec’s government. The goal is to recruit approximately 6,000 participants and see if the proposed treatment could severe pulmonary complications—such as major inflammatory storm—and deaths associated with COVID-19.

Patients are eligible for the COLCORONA trial if they have a positive diagnosis for COVID-19, are over the age of 40 and have not yet been hospitalized. Each participant will take either a drug or a placebo each day for a total of 30 days.

“Women who do not take contraceptives, those who are pregnant and those who are breastfeeding are not eligible for the clinical study,” according to a statement from the Montreal Heart Institute.

More information about the COLCORONA clinical trial, including contact information, is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

AHA issues a scientific statement on COVID-19 cardiac arrhythmias
History of COVID-19 doubles long-term risk of heart attack, stroke or death
Monitoring acute heart patients at home linked to considerable cost savings
A key update on how COVID-19 caused dangerous MIS-C inflammation in children
Q&A: Cardiologist Karen Joynt Maddox on why new healthcare policies are not improving outcomes
COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."